Treating Patients

By providing a replacement for the missing GAA enzyme,
Lumizyme® (alglucosidase alfa) can be an important part of a care plan
for patients with Pompe disease (GAA deficiency). Lumizyme
is administered by intravenous infusion, and should be reconstituted,
diluted, and administered by a health care professional.

Lumizyme is a hydrolytic lysosomal glycogen-specific enzyme
indicated for patients with Pompe disease (acid α-glucosidase (GAA) deficiency).

Patient photograph

Because of the potential risks of infusion reactions as well as more serious adverse events, close monitoring is necessary for patients receiving Lumizyme treatment. Life-threatening anaphylactic and severe allergic reactions have been observed in some patients during and up to three hours after Lumizyme infusions. Appropriate medical support should always be readily available whenever Lumizyme is administered.  Patients should be observed during and after each infusion by appropriate medical personnel familiar with Pompe disease and potential reactions to treatment.1 

Dosing & Administration

The recommended dosage of Lumizyme is 20 mg per kg of body weight, administered every two weeks as an intravenous infusion. Lumizyme should be reconstituted, diluted and administered by a healthcare professional. Infusions should be administered in a step-wise manner using an infusion pump, with patients carefully monitored throughout the approximately 4 hour process.

Learn more about Lumizyme Dosing & Administration


LUMIZYME® (alglucosidase alfa) is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (GAA deficiency).


  • Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions. Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment. Closely observe patients during and after alglucosidase alfa administration and be prepared to manage anaphylaxis and hypersensitivity reactions. Inform patients of the signs and symptoms of anaphylaxis, hypersensitivity reactions, and immune-mediated-reactions and have them seek immediate medical care should signs and symptoms occur.
  • Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload, and require additional monitoring.


Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa. If anaphylaxis or severe hypersensitivity reactions occur, immediately discontinue infusion and institute appropriate medical treatment. Appropriate medical support and monitoring measures should be available during infusion.

Immune-Mediated Reactions: Monitor patients for the development of systemic immunemediated reactions involving skin and other organs.

Risk of Acute Cardiorespiratory Failure: Patients with acute underlying respiratory illness and compromised cardiac and/or respiratory function may be at risk of acute cardiorespiratory failure. Caution should be exercised when administering alglucosidase alfa to patients susceptible to fluid volume overload. Appropriate medical support and monitoring measures should be available during infusion and some patients may require longer observation times.

Risk of Cardiac Arrhythmia and Sudden Cardiac Death during General Anesthesia for Central Venous Catheter Placement: Caution should be used when administering general anesthesia for the placement of a central venous catheter intended for alglucosidase alfa infusion.

Risk of Antibody Development: As with all therapeutic proteins, there is potential for immunogenicity. There is some evidence to suggest that some patients who develop high and sustained IgG antibody titers may experience reduced clinical efficacy. Patients should be monitored for IgG antibody formation every 3 months for 2 years and then annually thereafter.


The most frequently reported adverse reactions (≥ 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.


Pregnancy: Based on animal data, alglucosidase alfa may cause fetal harm.

Please see the Full Prescribing Information, for complete details, including boxed WARNING


  1. Lumizyme Full Prescribing Information, Genzyme Corporation

Reporting Adverse Reactions

You can report suspected adverse reactions to Sanofi Genzyme by either:

Calling 800-745-4447, option 2 OR
Sending us a detailed description by fax at 617-761-8506 or by email

You can also report directly to the FDA's MedWatch program: call 800-FDA-1088 or visit the MedWatch site.

Contact Us

Sanofi Genzyme
50 Binney Street
Cambridge, MA 02142

Tel : 617-768-9000
Fax : 617 252 7600
Toll free : 800-745-4447